Condition: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer · Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
This description comes directly from the study's public registry record.
Project Director · 858.263.4333 · medicalaffairs@zentalis.com
Always discuss trial participation with your own doctor first.
| Site 0170-USA Mitchell Cancer Institute | Mobile, Alabama, United States | Recruiting |
| Site 0143 - HonorHealth | Phoenix, Arizona, United States | Recruiting |
| Site 0102 - University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| Site 0258 - UC San Diego Moores Cancer Center | La Jolla, California, United States | Active Not Recruiting |
| Site 0287 - Ridley Tree Cancer Center | Santa Barbara, California, United States | Active Not Recruiting |
| Site 0135 - Rocky Mountain Cancer Centers | Lone Tree, Colorado, United States | Recruiting |
| Site 0158 - Hartford HealthCare | Hartford, Connecticut, United States | Recruiting |
| Site 0239 - Florida Cancer Specialists - East | Daytona Beach, Florida, United States | Recruiting |
| Site 0241 - Florida Cancer Specialist - North | Lecanto, Florida, United States | Recruiting |
| Site 0173 - Mount Sinai Medical Center | Miami Beach, Florida, United States | Recruiting |
| Site 0308 - Advent Health | Orlando, Florida, United States | Recruiting |
| Site 0108 - Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
+ 80 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05128825